Tejaswini Kulkarni

@tkulkarn1

#PulmCC Physician Scientist @uabmedicine| Director @ UAB-ILD program #curePF|@HarvardChanSPH alum|Wife and Triplet Mom #womeninmedicine| Tweets are mine.

Birmingham, AL scholars.uab.edu/display/tkulka… Joined November 2015

609 Following 770 Followers 885 Posts

Latest posts 5

Tejaswini Kulkarni @tkulkarn1 Oct 22, 2024

Our @AnnalsATS paper exploring factors associated with persistence of antifibrotic therapies among patients with IPF enrolled in @PFFORG registry is now in press; underscores the importance of addressing mental health. #curePF @ahajaricase @UABPulmonary

Tejaswini Kulkarni @tkulkarn1 Oct 14, 2024

Lessons learnt, cautious optimism and moving forward in clinical trials in ILD - #ICLAF2024

Tejaswini Kulkarni @tkulkarn1 Oct 13, 2024

Excellent panel discussing disparities and environmental exposures in ILDs - #ICLAF2024 #CurePF

Tejaswini Kulkarni @tkulkarn1 Oct 12, 2024

#ICLAF2024 kicking off with patient experience session and looking forward to 5 days of advances towards #curePF

Tejaswini Kulkarni @tkulkarn1 Aug 4, 2024

In clinical practice,there are often questions about approach to positive antibodies in the absence clinical signs of SARD. This study shows that IPF disease course and response to Pirfenidone did not differ by autoantibody status #CurePF @cnewto

Human Immunology News Verified account @humanimmunenews Aug 3, 2024

Dr. Tejaswini Kulkarni (@tkulkarn1) and researchers at @UABPulmonary evaluated the association of antinuclear #antibodies, #rheumatoid factor, and 💊 treatment outcomes of patients with #IPF from the 🩺 Phase III ASCEND trial.

@Pulmonary_Ther | bit.ly/3LPBsHp

View quoted post on X